双膦酸盐治疗骨转移癌骨痛及对血清钙磷的影响被引量：7

The effect of zoledronic and pamidronate acid in treating bone pain in bone metastases of malignant tumor and its impact on serum calcium and phosphorus

下载PDF

导出

摘要背景与目的：恶性肿瘤骨转移发生率有上升趋势,双膦酸盐已广泛应用于治疗骨转移癌.本研究旨在评价唑来膦酸与帕米膦酸治疗骨转移癌骨痛及对血清钙磷的影响.方法：对病理及影像确诊的100例骨转移癌患者分别使用唑来膦酸或帕米膦酸进行治疗,评价患者治疗1、2个月后疼痛缓解情况及血清钙、磷变化.结果：双瞵酸盐治疗1、2个月后,疼痛较前无明显变化（P＞0.05）,双膦酸盐治疗后中度疼痛似有下降趋势（x2=3.48,P=0.062）.骨转移癌患者血钙和血磷间存在直线正相关关系.双膦酸盐治疗1个月后,低钙血症的发生率为54%,治疗2个月后的发生率（56%）较治疗前（36%）显著增加（x2=6.55,P=0.011;x2=8.05,P=0.005）.治疗1个月后,血钙、血磷较治疗前显著降低（t=4.39,P=0.000;t=2.50,P=0.014）;治疗2个月后,血钙、血磷较治疗前仍低（t=4.32,P=0.000;t=2.49,P=0.010）.唑来膦酸和帕米膦酸相比,对骨痛缓解及血钙、血磷、碱性磷酸酶的影响差异无统计学意义（P＞0.05）.结论：唑来膦酸与帕米膦酸能缓解骨转移癌患者骨痛,引起低钙血症,打破原有钙磷相关关系.唑来膦酸与帕米膦酸比较对骨痛缓解及血钙、血磷及碱性磷酸酶的影响差异无统计学意义. Background and purpose： Bisphosphonates were widely used due to the rapidly increasing rate of bone metastases of malignant tumors. The aim of this study was to evaluate zoledronic and pamidronate acid therapy used for bone metastases of malignant tumors, and its effect on bone pain, serum calcium and phosphorus level. Methods： One hundred bone metastases cancer patients were diagnosed using pathological and imaging methods. After zoledronic or pamidronate acid intravenous infusion 1 and 2 months, ostealgia degree, serum calcium and phosphorus were observed respectively. Results： Ostealgia degree did not change after diphosphonate treatment at either 1 or 2 months （P〉0.005）. There was a linear correlation between serum calcium and phosphorus levels in bone metastases cancer patients before therapy and dismissed after therapy. The incidences of hypocalcium after 1 month （54%） and 2 months （56%） of diphosphonate treatment were more than those before the initial treatment （36%）（2,2=6.55, P=0.011; χ2=8.05, P=0.005）. Serum calcium and phosphorus decreased after 1 month （t=-4.39, P=0.000; t=-2.50, P=0.014） and 2 months of treatment （t=4.32, P=0.000; t=2.49, P=0.010）. There were no differences between the zoledronic and pamidronate acid groups in terms of ostealgia and serum calcium and phosphorus levels. Conclusion.. Zoledronic and pamidronate acid can relieve bone pain in bone metastases cancer patients and can also induce hypocalcium, break the relationship between calcium and phosphorus. There were no differences between zoledronic and pamidronate acid in treating bone pain and inducing hypocalcium and hypophosphorus.

作者王妹兴戴月娣陶莉李安琪江联萍肖谜杨梅

机构地区复旦大学附属肿瘤医院闵行分院

出处《中国癌症杂志》 CAS CSCD 北大核心 2010年第11期842-846,共5页 China Oncology

关键词唑来膦酸帕米膦酸骨痛钙磷 Zoledronic acid Pamidronate acid Bone pain Calcium Phosphorus

分类号 R730.53 [医药卫生—肿瘤]

引文网络
相关文献

参考文献9

1Rogers MJ,Frith JC,et al.The pharmacology of bisphosphonates and new insights into their mechanisms of action[J].J Bone Miner Res,1999,14:53.
2Peter R,Mishra V,Fraser WD.Severe hypocalcaemia after being given intravenous bisphosphonate[J].BMJ,2004,328:335-336.
3董梅,冯奉仪,张阳,谢广茹,王雅洁,刘基巍,宋三泰,周清华,任军,焦顺昌,李进,王秀问,陈强,王哲海,徐农,冯继峰.唑来膦酸治疗实体瘤骨转移或多发性骨髓瘤中重度骨痛的Ⅲ期临床研究[J].中华肿瘤杂志,2008,30(3):215-220. 被引量：20
4Lipton A.Treatment of bone metastases and bone pain with bisphosphonates[J].Support Cancer Ther,2007,4:92-100.
5Clemons MJ,Dranitsaris G,Ooi WS,et al.Phase Ⅱ trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy[J].J Clin Oncol,2006,24:4895-4900.
6Peter D.Bisphosphonate-associated adverse events[J].Hormones,2009,8:96-110.
7Harris ST,Gertz BJ,Genant HK,et al.The effect of short term treatment with alendronate on vertebral density.and biochemical markers of bone remodeling in early postmenopausal women[J].J Clin Endocrinol Metab,1993,76:1399-1406.
8Maalouf NM,Heller H J,Odvina CV,et al.Bisphosphonateinduced hypocalcemia:report of 3 cases and review of literature[J].Endocr Pract,2006,12:48-53.
9Donald SP,Scott WW,JS Funston,et al.Calcium and Phosphate[M] //.Barash,Paul G,Cullen,et al edit.Clinical Anesthesia.5th Edition.Lippincott Williams & Wilkins Publisher,2006:198-202.

二级参考文献14

1Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res, 1995, 10:1478-1487.
2Rogers MJ, Chilton KM, Coxon FP, et al. Bisphosphonates induce apoptosis in mouse maerophage-like ceils in vitro by a nitric oxideindependent mechanism. J Bone Miner Res, 1996, 11: 1482-1491.
3Rosen LS, Cordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disadium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 2003, 98 : 1735-1744.
4Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronie acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase Ⅲ, double-blind, randomized triM. J Clin Oncol, 2003, 21:3150-3157.
5Saad F, Gleason DM, Murray R, et al. A randomized, placebocontrolled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst, 2002, 94 : 1458-1468.
6Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol, 2005, 23:3314-3321.
7Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer, 2000, 88:2919-2926.
8Lipton A, Costa L, Ali SM, et al. Bone markers in the management of metastatic bone disease. Cancer Treat Rev, 2001, 27 : 181-185.
9Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer, 2003, 89:2031-2037.
10Brown JE, Cook R J, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst, 2005, 97:59-69.